GeneLink appoints James Monton to board
This article was originally published in Clinica
Consumer genomics specialist GeneLink has appointed James Monton to its board of directors, where he will serve on the audit and compensation committees. Mr Monton has "decades of product development and branding experience" in health and beauty care for Proctor & Gamble, and currently serves on the boards of Northern Kentucky University's Business School and the International Business Center. Longwood, Florida-based GeneLink's products include lipid metabolism, bone health and cardiovascular assessments, which analyse single nucleotide polymorphisms (SNPs) associated with these fields. It is also developing panels assessing dementia and Alzheimer's disease, and metabolic syndrome.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.